Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is a once-weekly injection, meaning the gap between shots should be seven days. That interval is not just a scheduling convenience — the medicine is designed around a weekly cycle, and keeping to it gives your body a steady, predictable level of tirzepatide. As a prescription-only medicine, your specific schedule is set by a prescriber during clinical assessment, not by a general rule.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide has a half-life of roughly five days. That means it lingers in your system long enough to bridge one week between doses while still maintaining a relatively stable concentration, but not so long that stacking two shots close together is safe. The seven-day interval is the schedule tested across the tirzepatide clinical programme, including the SURMOUNT-1 trial published in the New England Journal of Medicine, where participants received a weekly injection throughout the 72-week study. The licensing is built around that rhythm.
Going shorter than seven days is not recommended. It can push the concentration of the medicine higher than intended, which increases the likelihood of side effects (particularly nausea, vomiting and digestive discomfort) without adding any clinical benefit. Going much longer risks letting levels drop enough to reduce effectiveness. Seven days sits in that window on purpose.
The NHS patient information on tirzepatide confirms the weekly injection schedule and notes that the same day of the week each time is the practical target.
Life moves around, and your injection day sometimes needs to as well. A long weekend, a holiday, a medical procedure, there are reasonable moments when Wednesday's shot cannot happen on Wednesday. The Mounjaro Summary of Product Characteristics (SmPC) allows a change of injection day, provided the new timing lands at least four days after the most recent dose.
So if you usually inject on a Monday but want to move permanently to a Thursday, you'd take your next shot on the Thursday, as long as it falls four or more days after the previous Monday injection. After that, Thursday becomes your new day. This is a one-time adjustment, not a habit; the principle is that no two injections should ever be closer than four days apart.
For anyone who does a lot of their admin and ordering at the start of the month (thinking about payday, or managing Monday orders before the working week gets away from them) it's worth noting that choosing an injection day that aligns with when you'll reliably be at home and have your pen refrigerated reduces the chance of an accidental gap. Details on the Mounjaro injection process cover site rotation and technique if that is useful alongside timing.
Missing a dose is covered clearly in the SmPC and on the NHS tirzepatide page. The rule is simple: if fewer than four days have passed since you were due to inject, take the missed dose as soon as you remember and carry on with your usual weekly schedule from there. If four or more days have passed, skip that missed dose entirely and wait until your next scheduled day.
Do not take two shots to make up for a missed one. That is explicitly cautioned against, and doubling up replicates the too-close-together problem described above. More on what counts as too late for a missed Mounjaro dose explains the cut-off in practical terms, and how many days you can miss Mounjaro looks at what happens with longer gaps.
If gaps are becoming a pattern (perhaps because of supply issues, travel or side effects making you reluctant to inject) that is worth raising with your prescriber rather than quietly adjusting around it. Your clinical team at nume can discuss whether your schedule or dose needs reviewing.
Clinically, no specific weekday is better than another. What matters is that you can be consistent on whichever day you pick. Some people prefer a Monday so the week starts with a clear action. Others choose a Friday because they know they will be at home, can keep an eye on any initial side effects, and have the weekend to rest if needed. There is no right answer in the data.
Where day choice does have a practical edge: if you are earlier in treatment and still experiencing nausea after injecting, choosing a day where you have a quieter schedule the following 24 hours can make the experience more manageable. Many people find side effects are most noticeable in the first day or two after a new dose or dose increase, and they settle as the body adjusts, though some people also notice unexpected changes such as bleeding between periods while taking Mounjaro, which is worth being aware of. The MHRA's Yellow Card scheme is available to report any side effects you want to flag to regulators.
If you are thinking about what treatment at the right dose might look like for you, the practical first step is a clinical assessment. See the cost context for Mounjaro in the UK if that is also on your mind, or read about weight-loss treatment options more broadly before deciding. Our clinical team reviews every consultation personally.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.